News Novo Nordisk slumps on tougher 2026 financial outlook Squeezed by "unprecedented" pricing pressures, Novo Nordisk has forecast a decline in revenues this year.
News GLP-1 drugs linked to pancreatitis, gallbladder problems Users of weight-loss therapies based on GLP-1 agonists have been warned to be aware of a rare complication, pancreatitis, that can be severe.
News Wegovy pill shows strong early uptake, as rival looms Encouraging early sales data for oral Wegovy has buoyed Novo Nordisk, as Lilly waits for an FDA decision on its rival orforglipron, now due in Q2.
News Novo Nordisk launches Wegovy pill at $149 a month Novo Nordisk has followed through on its pledge for a swift launch of the Wegovy pill for weight loss, and revealed its pricing for self-payers.
News China delivers a win for Novo Nordisk on semaglutide IP Novo Nordisk has been handed a crucial legal win by China's Supreme Court, which backed the validity of its patent on GLP-1 agonist semaglutide.
News Novo Nordisk gets FDA okay for Wegovy pill The FDA has delivered a gift to Novo Nordisk ahead of the holiday season, with the prompt approval of its Wegovy pill.
News Servier snaps up cancer biotech Day One in $2.5bn deal Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
